Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 376

1.

Enhanced Factor IX Activity following Administration of AAV5-R338L "Padua" Factor IX versus AAV5 WT Human Factor IX in NHPs.

Spronck EA, Liu YP, Lubelski J, Ehlert E, Gielen S, Montenegro-Miranda P, de Haan M, Nijmeijer B, Ferreira V, Petry H, van Deventer SJ.

Mol Ther Methods Clin Dev. 2019 Sep 26;15:221-231. doi: 10.1016/j.omtm.2019.09.005. eCollection 2019 Dec 13.

2.

Elevated Lipoprotein(a) in Perinatally HIV-Infected Children Compared With Healthy Ethnicity-Matched Controls.

Van den Hof M, Klein Haneveld MJ, Blokhuis C, Scherpbier HJ, Jansen HPG, Kootstra NA, Dallinga-Thie GM, Van Deventer SJH, Tsimikas S, Pajkrt D; NOVICE study group .

Open Forum Infect Dis. 2019 Sep 2;6(9):ofz301. doi: 10.1093/ofid/ofz301. eCollection 2019 Sep.

3.

Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates.

Salas D, Kwikkers KL, Zabaleta N, Bazo A, Petry H, van Deventer SJ, Aseguinolaza GG, Ferreira V.

Blood Adv. 2019 Sep 10;3(17):2632-2641. doi: 10.1182/bloodadvances.2019000380.

4.

Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs.

Majowicz A, Nijmeijer B, Lampen MH, Spronck L, de Haan M, Petry H, van Deventer SJ, Meyer C, Tangelder M, Ferreira V.

Mol Ther Methods Clin Dev. 2019 May 28;14:27-36. doi: 10.1016/j.omtm.2019.05.009. eCollection 2019 Sep 13.

5.

AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models.

Spronck EA, Brouwers CC, Vallès A, de Haan M, Petry H, van Deventer SJ, Konstantinova P, Evers MM.

Mol Ther Methods Clin Dev. 2019 Mar 16;13:334-343. doi: 10.1016/j.omtm.2019.03.002. eCollection 2019 Jun 14.

6.

Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy.

Martier R, Liefhebber JM, García-Osta A, Miniarikova J, Cuadrado-Tejedor M, Espelosin M, Ursua S, Petry H, van Deventer SJ, Evers MM, Konstantinova P.

Mol Ther Nucleic Acids. 2019 Jun 7;16:26-37. doi: 10.1016/j.omtn.2019.02.001. Epub 2019 Feb 11.

7.

Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients.

Martier R, Liefhebber JM, Miniarikova J, van der Zon T, Snapper J, Kolder I, Petry H, van Deventer SJ, Evers MM, Konstantinova P.

Mol Ther Nucleic Acids. 2019 Mar 1;14:593-608. doi: 10.1016/j.omtn.2019.01.010. Epub 2019 Jan 30.

8.

Morphology of the first metatarsal head as a risk factor for hallux valgus interphalangeus.

van Deventer SJ, Strydom A, Saragas NP, Ferrao PNF.

Foot Ankle Surg. 2018 Dec 24. pii: S1268-7731(18)30060-2. doi: 10.1016/j.fas.2018.12.004. [Epub ahead of print]

PMID:
30630719
9.

AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.

Evers MM, Miniarikova J, Juhas S, Vallès A, Bohuslavova B, Juhasova J, Skalnikova HK, Vodicka P, Valekova I, Brouwers C, Blits B, Lubelski J, Kovarova H, Ellederova Z, van Deventer SJ, Petry H, Motlik J, Konstantinova P.

Mol Ther. 2018 Sep 5;26(9):2163-2177. doi: 10.1016/j.ymthe.2018.06.021. Epub 2018 Jun 25.

10.

AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.

Miniarikova J, Zimmer V, Martier R, Brouwers CC, Pythoud C, Richetin K, Rey M, Lubelski J, Evers MM, van Deventer SJ, Petry H, Déglon N, Konstantinova P.

Gene Ther. 2017 Oct;24(10):630-639. doi: 10.1038/gt.2017.71. Epub 2017 Aug 3.

11.

Molecular interactions shaping the tetraspanin web.

van Deventer SJ, Dunlock VE, van Spriel AB.

Biochem Soc Trans. 2017 Jun 15;45(3):741-750. doi: 10.1042/BST20160284. Review.

PMID:
28620035
12.

Tetraspanin microdomains control localized protein kinase C signaling in B cells.

Zuidscherwoude M, Dunlock VE, van den Bogaart G, van Deventer SJ, van der Schaaf A, van Oostrum J, Goedhart J, In 't Hout J, Hämmerling GJ, Tanaka S, Nadler A, Schultz C, Wright MD, Adjobo-Hermans MJW, van Spriel AB.

Sci Signal. 2017 May 9;10(478). pii: eaag2755. doi: 10.1126/scisignal.aag2755.

PMID:
28487417
13.

Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.

van Capelleveen JC, Kastelein JJ, Zwinderman AH, van Deventer SJ, Collins HL, Adelman SJ, Round P, Ford J, Rader DJ, Hovingh GK.

J Clin Lipidol. 2016 Sep-Oct;10(5):1137-1144.e3. doi: 10.1016/j.jacl.2016.06.006. Epub 2016 Jun 25.

PMID:
27678430
14.

Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease.

Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martier R, Koornneef A, Southwell AL, Hayden MR, van Deventer SJ, Petry H, Konstantinova P.

Mol Ther Nucleic Acids. 2016 Mar 22;5:e297. doi: 10.1038/mtna.2016.7.

15.

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.

Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, Rader DJ, Brewer HB, Barter PJ.

Lancet. 2015 Aug 1;386(9992):452-60. doi: 10.1016/S0140-6736(15)60158-1. Epub 2015 Jun 2.

PMID:
26047975
16.

Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery.

Majowicz A, Maczuga P, Kwikkers KL, van der Marel S, van Logtenstein R, Petry H, van Deventer SJ, Konstantinova P, Ferreira V.

J Gene Med. 2013 Jun-Jul;15(6-7):219-32. doi: 10.1002/jgm.2712.

PMID:
23658149
17.

Spatiotemporal analysis of organelle and macromolecular complex inheritance.

Menendez-Benito V, van Deventer SJ, Jimenez-Garcia V, Roy-Luzarraga M, van Leeuwen F, Neefjes J.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):175-80. doi: 10.1073/pnas.1207424110. Epub 2012 Dec 17.

18.

Murine CD4⁺CD25⁻ cells activated in vitro with PMA/ionomycin and anti-CD3 acquire regulatory function and ameliorate experimental colitis in vivo.

Majowicz A, van der Marel S, te Velde AA, Meijer SL, Petry H, van Deventer SJ, Ferreira V.

BMC Gastroenterol. 2012 Dec 3;12:172. doi: 10.1186/1471-230X-12-172.

19.

Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis.

van der Marel S, Majowicz A, Kwikkers K, van Logtenstein R, te Velde AA, De Groot AS, Meijer SL, van Deventer SJ, Petry H, Hommes DW, Ferreira V.

World J Gastroenterol. 2012 Aug 28;18(32):4288-99. doi: 10.3748/wjg.v18.i32.4288.

20.

Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs.

Borel F, Han R, Visser A, Petry H, van Deventer SJ, Jansen PL, Konstantinova P; Réseau Centre de Ressources Biologiques Foie (French Liver Biobanks Network), France.

Hepatology. 2012 Mar;55(3):821-32. doi: 10.1002/hep.24682. Epub 2012 Jan 13.

PMID:
21932399
21.

Genetically Modified Lactococcus lactis for Delivery of Human Interleukin-10 to Dendritic Cells.

Huibregtse IL, Zaat SA, Kapsenberg ML, Sartori da Silva MA, Peppelenbosch MP, van Deventer SJ, Braat H.

Gastroenterol Res Pract. 2012;2012:639291. doi: 10.1155/2012/639291. Epub 2011 Jul 27.

22.

In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs.

Borel F, van Logtenstein R, Koornneef A, Maczuga P, Ritsema T, Petry H, van Deventer SJ, Jansen PL, Konstantinova P.

J RNAi Gene Silencing. 2011;7:434-42. Epub 2011 Jun 17.

23.

Recombination-induced tag exchange to track old and new proteins.

Verzijlbergen KF, Menendez-Benito V, van Welsem T, van Deventer SJ, Lindstrom DL, Ovaa H, Neefjes J, Gottschling DE, van Leeuwen F.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):64-8. doi: 10.1073/pnas.0911164107. Epub 2009 Dec 14.

24.

Two Dot1 isoforms in Saccharomyces cerevisiae as a result of leaky scanning by the ribosome.

Frederiks F, Heynen GJ, van Deventer SJ, Janssen H, van Leeuwen F.

Nucleic Acids Res. 2009 Nov;37(21):7047-58. doi: 10.1093/nar/gkp765.

25.

Induction of antigen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo Dq8 transgenic mice.

Huibregtse IL, Marietta EV, Rashtak S, Koning F, Rottiers P, David CS, van Deventer SJ, Murray JA.

J Immunol. 2009 Aug 15;183(4):2390-6. doi: 10.4049/jimmunol.0802891. Epub 2009 Jul 27.

26.

A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis.

Hommes DW, Erkelens W, Ponsioen C, Stokkers P, Rauws E, van der Spek M, ten Kate F, van Deventer SJ.

J Clin Gastroenterol. 2008 May-Jun;42(5):522-6. doi: 10.1097/MCG.0b013e3181662426.

PMID:
18344886
27.

Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis.

Levels JH, Pajkrt D, Schultz M, Hoek FJ, van Tol A, Meijers JC, van Deventer SJ.

Biochim Biophys Acta. 2007 Dec;1771(12):1429-38. Epub 2007 Oct 12.

PMID:
17980169
28.

Muramyl dipeptide-induced differential gene expression in NOD2 mutant and wild-type Crohn's disease patient-derived dendritic cells.

Zelinkova Z, van Beelen AJ, de Kort F, Moerland PD, Ver Loren van Themaat E, te Velde AA, van Deventer SJ, de Jong EC, Hommes DW.

Inflamm Bowel Dis. 2008 Feb;14(2):186-94.

PMID:
17941075
29.

Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice.

Bleuming SA, He XC, Kodach LL, Hardwick JC, Koopman FA, Ten Kate FJ, van Deventer SJ, Hommes DW, Peppelenbosch MP, Offerhaus GJ, Li L, van den Brink GR.

Cancer Res. 2007 Sep 1;67(17):8149-55.

30.

Monocyte-derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile.

Gelderblom HC, Nijhuis LE, de Jong EC, te Velde AA, Pajkrt D, Reesink HW, Beld MG, van Deventer SJ, Jansen PL.

Liver Int. 2007 Sep;27(7):944-53.

PMID:
17696933
31.

Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.

Huibregtse IL, Snoeck V, de Creus A, Braat H, De Jong EC, Van Deventer SJ, Rottiers P.

Gastroenterology. 2007 Aug;133(2):517-28. Epub 2007 May 3.

PMID:
17681173
32.

Infliximab use in children and adolescents with inflammatory bowel disease.

de Ridder L, Benninga MA, Taminiau JA, Hommes DW, van Deventer SJ.

J Pediatr Gastroenterol Nutr. 2007 Jul;45(1):3-14. Review.

PMID:
17592358
33.

Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis.

Dekker E, van den Broek FJ, Reitsma JB, Hardwick JC, Offerhaus GJ, van Deventer SJ, Hommes DW, Fockens P.

Endoscopy. 2007 Mar;39(3):216-21.

PMID:
17385106
34.

An improved protocol for generation of immuno-potent dendritic cells through direct electroporation of CD14+ monocytes.

Milano F, van Baal JW, Rygiel AM, Bergman JJ, Van Deventer SJ, Kapsenberg ML, Peppelenbosch MP, Krishnadath KK.

J Immunol Methods. 2007 Apr 10;321(1-2):94-106. Epub 2007 Feb 5.

PMID:
17336322
35.

Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease.

te Velde AA, de Kort F, Sterrenburg E, Pronk I, ten Kate FJ, Hommes DW, van Deventer SJ.

Inflamm Bowel Dis. 2007 Mar;13(3):325-30.

PMID:
17206675
36.

Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.

Van den Brande JM, Koehler TC, Zelinkova Z, Bennink RJ, te Velde AA, ten Cate FJ, van Deventer SJ, Peppelenbosch MP, Hommes DW.

Gut. 2007 Apr;56(4):509-17. Epub 2006 Nov 2.

37.

Immunopathogenesis of IBD: insufficient suppressor function in the gut?

Huibregtse IL, van Lent AU, van Deventer SJ.

Gut. 2007 Apr;56(4):584-92. Epub 2006 Oct 17. Review. No abstract available.

38.

Treatment and prevention of Staphylococcus epidermidis experimental biomaterial-associated infection by bactericidal peptide 2.

Kwakman PH, te Velde AA, Vandenbroucke-Grauls CM, van Deventer SJ, Zaat SA.

Antimicrob Agents Chemother. 2006 Dec;50(12):3977-83. Epub 2006 Sep 25.

39.

Prevention of experimental colitis by parenteral administration of a pathogen-derived immunomodulatory molecule.

Braat H, McGuirk P, Ten Kate FJ, Huibregtse I, Dunne PJ, Hommes DW, Van Deventer SJ, Mills KH.

Gut. 2007 Mar;56(3):351-7. Epub 2006 Sep 4.

40.

Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN.

Löwenberg M, Verhaar AP, Bilderbeek J, Marle Jv, Buttgereit F, Peppelenbosch MP, van Deventer SJ, Hommes DW.

EMBO Rep. 2006 Oct;7(10):1023-9. Epub 2006 Aug 4.

41.

Immunomodulation of Crohn's disease using TNF-alpha neutralizing monoclonal antibodies.

Van Deventer SJ.

Clin Nutr. 1997 Dec;16(6):271-5. No abstract available.

PMID:
16844608
42.

Feasibility of evaluating Crohn's disease activity at 3.0 Tesla.

van Gemert-Horsthuis K, Florie J, Hommes DW, Lavini C, Reitsma JB, van Deventer SJ, Stoker J.

J Magn Reson Imaging. 2006 Aug;24(2):340-8.

PMID:
16786589
43.

A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease.

Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L.

Clin Gastroenterol Hepatol. 2006 Jun;4(6):754-9. Epub 2006 May 22.

PMID:
16716759
44.

A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.

van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr.

Aliment Pharmacol Ther. 2006 May 15;23(10):1415-25.

45.

Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study.

Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ.

Aliment Pharmacol Ther. 2006 Apr 15;23(8):1127-36.

46.

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.

Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T.

Gut. 2006 Aug;55(8):1138-44. Epub 2006 Feb 21.

47.

Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.

Stokkers PC, Deley M, Van Der Spek M, Verberne HJ, Van Deventer SJ, Hommes DW.

Scand J Gastroenterol. 2006 Feb;41(2):200-4.

PMID:
16484125
48.

Polyp miss rate determined by tandem colonoscopy: a systematic review.

van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E.

Am J Gastroenterol. 2006 Feb;101(2):343-50. Review.

PMID:
16454841
49.

Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression.

Zelinkova Z, Derijks LJ, Stokkers PC, Vogels EW, van Kampen AH, Curvers WL, Cohn D, van Deventer SJ, Hommes DW.

Clin Gastroenterol Hepatol. 2006 Jan;4(1):44-9.

PMID:
16431304
50.

Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease.

Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, van Deventer SJ, Hommes DW, Hooymans PM.

Ther Drug Monit. 2006 Feb;28(1):45-50.

PMID:
16418693

Supplemental Content

Loading ...
Support Center